British Journal of Haematology · 2002 · 105 citations · 6 references
PharmacyPharmacologyPharmacotherapyCancer Drug Toxicity ManagementDermatopathologyHypersensitivityDrug-induced Skin ReactionsImmune-related Adverse EventsSkin IrritationBlast CrisisChronic Myeloid Leukemia TherapyCutaneous Adverse EventsCutaneous Drug EruptionsCutaneous Drug ReactionsJak InhibitorsSevere Cutaneous Adverse ReactionsTyrosine Kinase Inhibitor Therapy
Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life-threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.
6
Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2001 · 2.7K citations · Full text
Medicine, Hematology, Oncology +17